Physician profile

Daniel Hogan

Columbia, MO

NPI 1679154496

$1,194.19

in general payments reported to CMS, 2019-2025

4 companies · $792 in 2025

The $792 reported for 2025 was more than what 85% of providers received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$928.46
Travel and Lodging$265.73

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Stryker Corporation $618.94 2023-2025 Triathlon, Mako, Invision
Paragon 28, INC. $511.62 2025 Ankle Fracture
Treace Medical Concepts, INC. $46.37 2025
Medtronic, INC. $17.26 2024 Infinity Occipitocervical Upper Thoracic System

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Daniel Hogan

$1,194.19

in general payments reported 2019-2025

Years
2023-2025
Top company
Stryker Corporation
Context
The $792 reported for 2025 was more than what 85% of providers received nationally.

https://glasscript.com/doctor/11555440/daniel-hogan

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.